Related Experiment Video

Updated: Jun 6, 2026

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.6K

ANMCO position paper 'Hypertrophic cardiomyopathy: from diagnosis to treatment'

Cristina Chimenti1, Attilio Iacovoni2, Andrea Montalto3

  • 1UOC Malattie Apparato Cardiovascolare, AOU 'Policlinico Umberto I', Dipartimento di Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Viale del Policlinico, 155, Roma 00161, Italy.

European Heart Journal Supplements : Journal of the European Society of Cardiology
|May 19, 2025
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) is a genetic heart condition affecting 1:500 people. New myosin-inhibiting drugs offer novel treatment options for obstructive HCM, improving patient classification and tailored therapy.

Area of Science:

  • Cardiology
  • Genetics
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a prevalent genetic heart disease (1:500) marked by increased left ventricular wall thickness without external load.
  • Left ventricular outflow tract obstruction in HCM significantly reduces functional capacity and predicts sudden cardiac death and heart failure progression.

Purpose of the Study:

  • To enhance cardiologists' understanding of HCM, covering epidemiology, genetics, and pathology.
  • To define diagnostic criteria and risk stratification methods for personalized HCM treatment.
  • To introduce new therapeutic strategies, including novel myosin-inhibiting drugs.

Main Methods:

  • Review of epidemiological, genetic, and pathological data on HCM.
  • Analysis of diagnostic criteria and instrumental methods for risk stratification.
  • Evaluation of current and emerging therapeutic options for obstructive HCM.

Main Results:

  • HCM is characterized by asymmetric hypertrophy, often affecting the basal septum.
  • Left ventricular outflow tract obstruction is a key complication impacting prognosis.
  • New pharmacological treatments targeting cardiac myosin are now available for symptomatic obstructive HCM.

Conclusions:

  • Accurate clinical-therapeutic classification is crucial for optimal HCM management.
  • Emerging therapies offer new hope for patients with obstructive HCM.
  • A comprehensive approach integrating diagnosis, risk stratification, and tailored therapy is essential for improving HCM patient outcomes.

Keywords:
DiagnosisHeart failureHypertrophic cardiomyopathyTherapyVentricular hypertrophy

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

4.7K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.0K

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...